2c76b1fd5432bdaab8086ecdf7471105 pmc_34201729.pdf da4c90a03a25c5b4ac697b7ad58878f33650827d pmc_34201729.pdf 09325fdbfb72da0168c5efa63a977659258f008974551caaf365971d3751d2c3 pmc_34201729.pdf Title: Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study Subject: The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. The REBA study (real-world experience with brolucizumab in wet AMD) was a retrospective, observational, multicentric study that included 78 consecutive patients (105 eyes), with neovascular AMD, who received brolucizumab therapy. Both treatment-naive and switch-therapy patients were included. Switch therapy was based either on fluid recurrence, fluid recalcitrance, or inability to extend beyond q4/q6. All relevant data were collected. The primary outcome measure was change in best-corrected visual acuity (BCVA) over time. Secondary outcome measures included determination of change in central subfield thickness (CST) and complications. The mean baseline BCVA was 49.4 5.4 letters and 40 3.2 letters, and corresponding mean BCVA gain was +11.9 3.9 letters (p = 0.011) and +10.4 4.8 letters (p = 0.014) in the treatment-naive and switch-therapy groups, respectively. The change in CST was significantly decreased in the treatment-naive (p = 0.021) and the switch-therapy (p = 0.013) groups. The mean follow-up was 10.4 months in both groups. One patient in the switch-therapy group developed vascular occlusion and another a macular hole after the fifth brolucizumab injection. Both patients recovered uneventfully. In conclusion, patients showed a very good anatomical and functional response to brolucizumab therapy in the real world, regardless of prior treatment status, until the end of the follow-up period. Two significant untoward events were noted. Keywords: age-related macular degeneration; anti-vascular endothelial growth factor; brolucizumab; exudation; switch therapy Author: Alper Bilgic, Laurent Kodjikian, Francesc March de Ribot, Vaishali Vasavada, Jesus H. Gonzalez-Cortes, Amro Abukashabah, Aditya Sudhalkar and Thibaud Mathis Creator: LaTeX with hyperref package Producer: pdfTeX-1.40.18 CreationDate: Thu Jul 1 03:26:00 2021 CEST ModDate: Thu Jul 1 03:31:19 2021 CEST Custom Metadata: no Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 12 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 4117376 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- XZQLWO+URWPalladioL-Ital Type 1 Custom yes yes no 10 0 VIDVLT+URWPalladioL-Bold Type 1 Custom yes yes no 15 0 LGFTMK+URWPalladioL-Roma Type 1 Custom yes yes no 19 0 TFNRKZ+CMSY10 Type 1 Builtin yes yes no 23 0 OPZDHV+VnURWPalladioL Type 1 Custom yes yes no 27 0 XPUSBJ+TimesNewRomanPS-BoldItalicMT Type 1C WinAnsi yes yes no 36 0 BSDWLC+TimesNewRomanPSMT Type 1C WinAnsi yes yes no 39 0 MCBCCI+SourceSansRoman-Regular Type 1C Custom yes yes no 61 0 MCBCCM+SourceSansRoman.613wght Type 1C Custom yes yes no 65 0 MCBCCO+SourceSansRoman-Bold Type 1C Custom yes yes no 69 0 OVNEXW+EURM10 Type 1 Builtin yes yes no 84 0 IJPFBL+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 94 0 IJPFBN+PalatinoLinotype TrueType WinAnsi yes yes no 97 0 IJPFCO+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 100 0 IJPGAK+Symbol Type 1C Custom yes yes yes 115 0 IJPFBL+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 120 0 IJPFBN+PalatinoLinotype TrueType WinAnsi yes yes no 123 0 IJPFCO+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 126 0 IJPGAK+Symbol Type 1C Custom yes yes yes 137 0 IJPFBL+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 142 0 IJPFBN+PalatinoLinotype TrueType WinAnsi yes yes no 145 0 IJPFCO+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 148 0 IJPGAK+Symbol Type 1C Custom yes yes yes 158 0 IJPFBL+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 163 0 IJPFBN+PalatinoLinotype TrueType WinAnsi yes yes no 166 0 IJPFCO+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 169 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2024-10-02 03:12:26 CEST RepresentationInformation: pmc_34201729.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2023-03-31 12:14:19 CEST Size: 4117376 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 291 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Destination: section.1 Item: Title: Materials and Methods Destination: section.2 Children: Item: Title: Eligibility Destination: subsection.2.1 Item: Title: Definitions Destination: subsection.2.2 Item: Title: Grouping Destination: subsection.2.3 Item: Title: Acquisition of Data Destination: subsection.2.4 Item: Title: Follow-Up Destination: subsection.2.5 Item: Title: Outcome Measures Destination: subsection.2.6 Item: Title: Statistical Analysis Destination: subsection.2.7 Item: Title: Results Destination: section.3 Children: Item: Title: Treatment-Naïve Group Destination: subsection.3.1 Item: Title: Visual Gain Destination: subsection.3.2 Item: Title: Recurrence Destination: subsection.3.3 Item: Title: Switch-Therapy Group Destination: subsection.3.4 Item: Title: Visual Gain Destination: subsection.3.5 Item: Title: Adverse Events Destination: subsection.3.6 Item: Title: Discussion Destination: section.4 Item: Title: References Destination: section.4 Info: Title: Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study Author: Alper Bilgic, Laurent Kodjikian, Francesc March de Ribot, Vaishali Vasavada, Jesus H. Gonzalez-Cortes, Amro Abukashabah, Aditya Sudhalkar and Thibaud Mathis Subject: The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. The REBA study (real-world experience with brolucizumab in wet AMD) was a retrospective, observational, multicentric study that included 78 consecutive patients (105 eyes), with neovascular AMD, who received brolucizumab therapy. Both treatment-naive and switch-therapy patients were included. Switch therapy was based either on fluid recurrence, fluid recalcitrance, or inability to extend beyond q4/q6. All relevant data were collected. The primary outcome measure was change in best-corrected visual acuity (BCVA) over time. Secondary outcome measures included determination of change in central subfield thickness (CST) and complications. The mean baseline BCVA was 49.4 5.4 letters and 40 3.2 letters, and corresponding mean BCVA gain was +11.9 3.9 letters (p = 0.011) and +10.4 4.8 letters (p = 0.014) in the treatment-naive and switch-therapy groups, respectively. The change in CST was significantly decreased in the treatment-naive (p = 0.021) and the switch-therapy (p = 0.013) groups. The mean follow-up was 10.4 months in both groups. One patient in the switch-therapy group developed vascular occlusion and another a macular hole after the fifth brolucizumab injection. Both patients recovered uneventfully. In conclusion, patients showed a very good anatomical and functional response to brolucizumab therapy in the real world, regardless of prior treatment status, until the end of the follow-up period. Two significant untoward events were noted. Keywords: age-related macular degeneration; anti-vascular endothelial growth factor; brolucizumab; exudation; switch therapy Creator: LaTeX with hyperref package Producer: pdfTeX-1.40.18 CreationDate: Thu Jul 01 03:26:00 CEST 2021 ModDate: Thu Jul 01 03:31:19 CEST 2021 ID: 0x58603d487a59912b2b47c7c9cdc54151, 0x58603d487a59912b2b47c7c9cdc54151 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: LGFTMK+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 246 FontDescriptor: FontName: LGFTMK+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: OVNEXW+EURM10 FontSubset: true FirstChar: 22 LastChar: 22 FontDescriptor: FontName: OVNEXW+EURM10 Flags: Symbolic FontBBox: -32, -243, 1060, 720 FontFile: true Font: BaseFont: TFNRKZ+CMSY10 FontSubset: true FirstChar: 6 LastChar: 15 FontDescriptor: FontName: TFNRKZ+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true Font: BaseFont: XZQLWO+URWPalladioL-Ital FontSubset: true FirstChar: 2 LastChar: 239 FontDescriptor: FontName: XZQLWO+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: OPZDHV+VnURWPalladioL FontSubset: true FirstChar: 161 LastChar: 226 FontDescriptor: FontName: OPZDHV+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: VIDVLT+URWPalladioL-Bold FontSubset: true FirstChar: 3 LastChar: 239 FontDescriptor: FontName: VIDVLT+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 35, 759, 176, 795 Annotation: Subtype: Link Rect: 515, 759, 560, 795 Annotation: Subtype: Link Rect: 199, 659, 210, 673 Annotation: Subtype: Link Rect: 332, 659, 343, 673 Annotation: Subtype: Link Rect: 156, 647, 168, 661 Annotation: Subtype: Link Rect: 143, 382, 154, 391 Annotation: Subtype: Link Rect: 35, 370, 154, 379 Annotation: Subtype: Link Rect: 35, 358, 75, 367 Annotation: Subtype: Link Rect: 35, 162, 97, 184 Annotation: Subtype: Link Rect: 153, 89, 154, 98 Annotation: Subtype: Link Rect: 35, 77, 147, 86 Annotation: Subtype: Link Rect: 541, 130, 548, 139 ActionDest: 180 Annotation: Subtype: Link Rect: 549, 130, 556, 139 ActionDest: 180 Annotation: Subtype: Link Rect: 501, 105, 508, 114 ActionDest: 180 Annotation: Subtype: Link Rect: 216, 80, 223, 89 ActionDest: 180 Annotation: Subtype: Link Rect: 445, 67, 452, 76 ActionDest: 180 Annotation: Subtype: Link Rect: 455, 67, 462, 76 ActionDest: 180 Annotation: Subtype: Link Rect: 131, 17, 268, 28 Annotation: Subtype: Link Rect: 422, 17, 558, 28 Annotation: Subtype: Link Rect: 35, 482, 87, 501 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 194, 694, 206, 703 ActionDest: 180 Annotation: Subtype: Link Rect: 327, 644, 339, 653 ActionDest: 180 Annotation: Subtype: Link Rect: 476, 632, 488, 641 ActionDest: 180 Annotation: Subtype: Link Rect: 488, 632, 500, 641 ActionDest: 180 Annotation: Subtype: Link Rect: 324, 355, 336, 364 ActionDest: 180 Annotation: Subtype: Link Rect: 527, 304, 539, 313 ActionDest: 180 Annotation: Subtype: Link Rect: 212, 173, 219, 182 ActionDest: 180 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 491, 286, 498, 298 ActionDest: 88 Annotation: Subtype: Link Rect: 536, 264, 543, 273 ActionDest: 180 Annotation: Subtype: Link Rect: 544, 264, 556, 273 ActionDest: 180 Page: Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 533, 168, 540, 180 ActionDest: 104 Page: Sequence: 5 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 521, 465, 528, 477 ActionDest: 107 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 393, 613, 400, 625 ActionDest: 131 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 417, 729, 424, 741 ActionDest: 152 Page: Sequence: 9 Annotations: Annotation: Subtype: Link Rect: 340, 506, 352, 515 ActionDest: 180 Annotation: Subtype: Link Rect: 500, 405, 512, 414 ActionDest: 180 Annotation: Subtype: Link Rect: 497, 192, 509, 201 ActionDest: 180 Annotation: Subtype: Link Rect: 412, 179, 424, 188 ActionDest: 180 Annotation: Subtype: Link Rect: 394, 154, 406, 163 ActionDest: 184 Annotation: Subtype: Link Rect: 406, 154, 418, 163 ActionDest: 184 Page: Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 530, 669, 542, 678 ActionDest: 180 Annotation: Subtype: Link Rect: 360, 594, 372, 603 ActionDest: 184 Annotation: Subtype: Link Rect: 373, 594, 385, 603 ActionDest: 184 Annotation: Subtype: Link Rect: 544, 381, 556, 390 ActionDest: 184 Annotation: Subtype: Link Rect: 220, 330, 232, 339 ActionDest: 184 Annotation: Subtype: Link Rect: 434, 318, 446, 327 ActionDest: 184 Annotation: Subtype: Link Rect: 413, 280, 425, 289 ActionDest: 184 Page: Sequence: 11 Annotations: Annotation: Subtype: Link Rect: 302, 582, 339, 593 Annotation: Subtype: Link Rect: 345, 582, 381, 593 Annotation: Subtype: Link Rect: 59, 548, 97, 559 Annotation: Subtype: Link Rect: 519, 525, 556, 536 Annotation: Subtype: Link Rect: 195, 490, 232, 501 Annotation: Subtype: Link Rect: 239, 490, 275, 501 Annotation: Subtype: Link Rect: 122, 456, 159, 467 Annotation: Subtype: Link Rect: 166, 456, 202, 467 Annotation: Subtype: Link Rect: 389, 432, 426, 444 Annotation: Subtype: Link Rect: 201, 398, 238, 409 Annotation: Subtype: Link Rect: 430, 363, 467, 374 Annotation: Subtype: Link Rect: 474, 363, 510, 374 Annotation: Subtype: Link Rect: 411, 329, 448, 340 Annotation: Subtype: Link Rect: 279, 294, 317, 305 Annotation: Subtype: Link Rect: 59, 261, 97, 271 Annotation: Subtype: Link Rect: 103, 261, 139, 271 Annotation: Subtype: Link Rect: 240, 191, 277, 202 Annotation: Subtype: Link Rect: 283, 191, 319, 202 Annotation: Subtype: Link Rect: 505, 156, 543, 167 Annotation: Subtype: Link Rect: 314, 133, 351, 144 Annotation: Subtype: Link Rect: 86, 99, 218, 110 Page: Sequence: 12 Annotations: Annotation: Subtype: Link Rect: 59, 720, 97, 730 Annotation: Subtype: Link Rect: 95, 685, 133, 696 Annotation: Subtype: Link Rect: 139, 685, 175, 696 Annotation: Subtype: Link Rect: 333, 662, 370, 673 Annotation: Subtype: Link Rect: 109, 628, 146, 638 Annotation: Subtype: Link Rect: 389, 604, 427, 615 Annotation: Subtype: Link Rect: 433, 604, 469, 615 Annotation: Subtype: Link Rect: 206, 570, 243, 581 Annotation: Subtype: Link Rect: 250, 570, 286, 581 Annotation: Subtype: Link Rect: 108, 536, 145, 546 Annotation: Subtype: Link Rect: 152, 536, 188, 546 Annotation: Subtype: Link Rect: 415, 512, 453, 523 Annotation: Subtype: Link Rect: 459, 512, 495, 523 Checksum: 1d70529e Type: CRC32 Checksum: 2c76b1fd5432bdaab8086ecdf7471105 Type: MD5 Checksum: da4c90a03a25c5b4ac697b7ad58878f33650827d Type: SHA-1 Checksum: 09325fdbfb72da0168c5efa63a977659258f008974551caaf365971d3751d2c3 Type: SHA-256